ON DEMAND WEBINAR
Enhancing MRD Detection in AML: Insights From ASST Papa Giovanni XXIII Hospital’s NGS-Based Approach
Measurable Residual Disease (MRD) is a crucial biomarker for analyzing and tracking tumor evolution, evaluating treatment effectiveness, and predicting relapse in acute myeloid leukemia (AML). Among the various technologies used to detect MRD, next-generation sequencing (NGS) stands out for its exceptional sensitivity and specificity. Guidelines from the European LeukemiaNet provide recommendations for MRD assessment, including the use of NGS, to ensure consistency and reliability in clinical practice. However, NGS faces challenges, particularly related to its limit of detection (LOD). The intrinsic error rate of NGS can interfere with the clear discrimination of target signals from background noise, making it difficult to detect very low levels of MRD. This limitation necessitates careful standardization of bioinformatics pipelines to ensure accurate results. In this webinar, Silvia Salmoiraghi, biologist at the Ultra-Specialist Laboratory of Clinical Pathology-Hematology, at ASST Papa Giovanni XXIII Hospital in Bergamo, Italy, will discuss the performance of the Sophia DDM Residual Acute Myeloid (RAM) Solution.
Salmoiraghi will cover:
- The process of evaluating and implementing this new capture-based NGS application.
- The accurate detection of MRD while assessing multiple biomarkers.
- The advantages of adopting an NGS-based application compared to other technologies.
Speaker:
Silvia Salmoiraghi, PhD
Bio:
Biologist, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa, Giovanni XXIII Hospital, Bergamo, Italy Silvia Salmoiraghi graduated in biotechnology and molecular medicine at the University of Milano and then she obtained a doctorate in translational and molecular medicine at the University of Milano Bicocca. Since 2005, she has worked as a biologist at the Ultra-Specialist Laboratory of Clinical Pathology-Hematology at ASST Papa Giovanni XXIII. Her primary focus is on the genetics of hematologic malignancies, particularly the evaluation of molecular markers that guide clinical therapeutic decisions.